✨ Free AI Report
Travere Therapeutics, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Travere Therapeutics, Inc.
Company Research

Travere Therapeutics, Inc.: Business Overview, Financials & Competitive Analysis

Travere Therapeutics, Inc. scores 8/10 on the AskCyborg Cyborg Score (Strong). Rare kidney disease specialist with accelerating FILSPARI adoption, strong cash position, near-term FSGS approval catalyst, and meaningful clinical pipeline expansion opportunity. The company achieved $410.5 million in total 2025 product sales with FILSPARI showing 144% YoY growth. Travere ended 2025 with $323 million in cash and equivalents, providing strong.

What is Travere Therapeutics, Inc.'s industry? Travere Therapeutics, Inc. (travere.com) operates in Biopharmaceutical - Rare Kidney and Metabolic Diseases. AskCyborg classifies Travere Therapeutics, Inc. under Biopharmaceutical - Rare Kidney and Metabolic Diseases in its company registry.

Travere Therapeutics is a biopharmaceutical company that identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. The company is experiencing exceptional commercial moment...

8/ 10Strong

Cyborg Score thesis

Rare kidney disease specialist with accelerating FILSPARI adoption, strong cash position, near-term FSGS approval catalyst, and...

Read the full analyst-debate transcript →
Industry Biopharmaceutical - Rare Kidney and Metabolic Diseases
3 named competitors
4 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 19, 2026
AI-Generated Research
30+ Page Report

Get the Latest Travere Therapeutics, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Travere Therapeutics, Inc.

AskCyborg analysts argue the bull and bear cases for Travere Therapeutics, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Travere Therapeutics, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Travere Therapeutics, Inc. Overview

Pro stress-test →

Travere Therapeutics is a biopharmaceutical company that identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. The company is experiencing exceptional commercial momentum with FILSPARI generating $322 million in 2025, a 144% increase year-over-year.

Strategic Profile

Pro stress-test →

FILSPARI (sparsentan) is a once-daily oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy, and the company also markets Thiola and Thiola EC for cystinuria treatment. The company is pursuing FDA approval for FILSPARI in FSGS with a PDUFA target action date of January 13, 2026.

Competitive Landscape

Pro stress-test →

Travere competes in the rare kidney disease market alongside other specialized biopharmaceutical companies. The company faces challenges related to product dependence and supply chain management, but has opportunities for growth through pipeline expansion and global market penetration. The company's focus on rare kidney and metabolic diseases provides a differentiated market position.

Industry Context

Travere Therapeutics, Inc. operates in Biopharmaceutical - Rare Kidney and Metabolic Diseases.

Key facts

Founded: 2008 · Headquarters: San Diego, US · Revenue: $410M · Market cap: $1.3B

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Travere Therapeutics, Inc..

  • U.S. FILSPARI reached 908 new prescriber starts and $103 million in net product sales in Q4 2025
  • Company expanded field team to over 100 personnel targeting high prescriber overlap between IgAN and FSGS
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • January 20262025 U.S. net product sales reached $410 million
  • January 2026FILSPARI FSGS approval decision expected January 13, 2026
  • +2 moreTrack every material event for Travere Therapeutics, Inc. as it happens. Explore monitoring →
Get alerted when Travere Therapeutics, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

FSGS and IgAN treatmentsDeveloping therapies for kidney disease→Cystinuria treatmentRare disease biopharmaceutical→Rare kidney disease focusLupus nephritis and other kidney disorders→

Compare Travere Therapeutics, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Travere Therapeutics, Inc. operates in Biopharmaceutical - Rare Kidney and Metabolic Diseases. See how the rest of the sector scores on the Cyborg framework.

Browse Biopharmaceutical - Rare Kidney and Metabolic Diseases research →
NEW · MCP server

Ask your AI assistant about Travere Therapeutics, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Travere Therapeutics, Inc. and its top competitor on Cyborg Score”
“What did Travere Therapeutics, Inc. do this quarter?”
“Is Travere Therapeutics, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com · Terms of Service

Frequently asked questions

What does Travere Therapeutics, Inc. do?+
Travere Therapeutics is a biopharmaceutical company that identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. The company is experiencing exceptional commercial moment...
What is Travere Therapeutics, Inc.'s Cyborg Score?+
Travere Therapeutics, Inc. has a Cyborg Score of 8/10 (Strong). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Travere Therapeutics, Inc.'s main competitors?+
Named competitors include FSGS and IgAN treatments, Cystinuria treatment, Rare kidney disease focus. The full competitive landscape is in the AskCyborg report.
How can I get the full Travere Therapeutics, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Travere Therapeutics, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Travere Therapeutics, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.